Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR mHealth and uHealth

Date Submitted: May 17, 2019
Open Peer Review Period: May 21, 2019 - Jul 16, 2019
Date Accepted: Aug 30, 2019
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Evaluation of Mobile Apps Targeted at Patients With Spondyloarthritis for Disease Monitoring: Systematic App Search

Kwan YH, Ong WJ, Xiong M, Leung YY, Phang JK, Wang CTM, Fong W

Evaluation of Mobile Apps Targeted at Patients With Spondyloarthritis for Disease Monitoring: Systematic App Search

JMIR Mhealth Uhealth 2019;7(10):e14753

DOI: 10.2196/14753

PMID: 31661080

PMCID: 6913729

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Evaluation of Mobile Apps Targeted at Patients With Spondyloarthritis for Disease Monitoring: Systematic App Search

  • Yu Heng Kwan; 
  • Wei Jie Ong; 
  • Mengfei Xiong; 
  • Ying Ying Leung; 
  • Jie Kie Phang; 
  • Charmaine Tze May Wang; 
  • Warren Fong

Background:

There are many apps developed for patients with spondyloarthritis in the market, but their purpose and quality are not objectively evaluated.

Objective:

The objective of this study was to identify and evaluate existing publicly available, high-quality apps that use validated measurement instruments for monitoring spondyloarthritis disease activity.

Methods:

We conducted a review of apps available on the Apple App Store and the Google Play Store based on a combination of keywords and inclusion and exclusion criteria. Validated disease activity measurement instruments were identified. Data regarding app characteristics, including the presence of validated disease activity measurement, were extracted. The Mobile App Rating Scale (MARS) was used to review the apps for user experience.

Results:

A total of 1253 apps were identified in the app stores, and 5 apps met the criteria and were further analyzed. Moreover, 2 apps (MySpA and Group for Research and Assessment of Psoriasis and Psoriatic Arthritis App) contained some of the validated disease activity monitoring instruments for specific spondyloarthritis subtypes. These 2 apps were also rated good on the MARS (with total mean scores ≥4 out of 5), whereas the other apps scored poorly in comparison.

Conclusions:

There are 2 high-quality spondyloarthritis disease activity monitoring apps publicly available, but they only target 2 spondyloarthritis subtypes—ankylosing spondylitis and psoriatic arthritis. There is a lack of high-quality apps that can measure disease activity for other spondyloarthritis subtypes, and no app that consolidates all validated disease activity instruments across subtypes was available.


 Citation

Please cite as:

Kwan YH, Ong WJ, Xiong M, Leung YY, Phang JK, Wang CTM, Fong W

Evaluation of Mobile Apps Targeted at Patients With Spondyloarthritis for Disease Monitoring: Systematic App Search

JMIR Mhealth Uhealth 2019;7(10):e14753

DOI: 10.2196/14753

PMID: 31661080

PMCID: 6913729

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.